For the Inventor, By the Inventor

Enter assignee name

Alameda, CA, United States of America

Exelixis, Inc.

USPTO Granted Patents = 175

CIPO Patents = 16

EPO Patents = 66

Trademarks = 14

Forward Citations = 1,509

Loading Chart...

Loading Chart...

311 inventors (with patents filed for the assignee):

Wei Xu (26 out of 81 patents)

John M Nuss (26 out of 54 patents)

Yong Wang (24 out of 36 patents)

4. Lynne Canne Bannen (20 out of 24 patents)

5. James William Leahy (20 out of 25 patents)

6. Khalid Ali Shah (19 out of 28 patents)

7. Dana T Aftab (17 out of 18 patents)

8. Neel Kumar Anand (15 out of 39 patents)

9. Richard Martin (15 out of 54 patents)

10. Lori Friedman (15 out of 22 patents)

11. Joerg Bussenius (14 out of 19 patents)

12. Kenneth D Rice (14 out of 23 patents)

13. Helen Louise Francis-Lang (14 out of 15 patents)

14. Peter Lamb (13 out of 13 patents)

15. Tsze Tsang (13 out of 33 patents)

Core Competencies:

Crystalline Solid Forms

Quinoline Compounds

Kinase Inhibitors

Adenosine Receptor Antagonists

C-Met Modulators

Cabozantinib

Malate Salts

Drug Combinations

Pharmaceutical Compositions

MEK Inhibitors

Lymphoproliferative Malignancies

Osteoporosis Treatment

175 patents: Sort by Forward Citations

1. 12503438 - Compounds for the treatment of kinase-dependent disorders (2025-12-23),

2. 12497367 - Processes for the preparation of a kinase inhibitor (2025-12-16),

3. 12486233 - Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-12-02),

4. 12371428 - Pyridone compounds and methods of use (2025-07-29),

5. 12275706 - Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer (2025-04-14),

6. 12264161 - Heterocyclic adenosine receptor antagonists (2025-04-01),

7. 12227481 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-02-18),

8. 12195475 - Compounds for the treatment of kinase-dependent disorders (2025-01-14),

9. 12128039 - Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds (2024-10-29),

10. 12084496 - Anti-ROR antibody constructs (2024-09-10),

11. 12017995 - Crystalline forms and salt forms of a kinase inhibitor (2024-06-25),

12. 12016854 - Liquid dosage forms to treat cancer (2024-06-25),

13. 11969419 - Method of treating cancer (2024-04-30),

14. 11760726 - Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-09-19),

15. 11718622 - Heterocyclic adenosine receptor antagonists (2023-08-08),

Exelixis, Inc. is a biotechnology company focused on the discovery, development and commercialization of new medicines to improve the treatment of cancer and other serious diseases. With a robust pipeline of potential therapies, Exelixis is committed to advancing science to develop innovative treatments that can make a meaningful difference in patients' lives.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

175 Patents

#3 in Alameda, CA

#510 in California

#2,221 in US

#4,622 in the World

Alameda, CA, United States of America

Exelixis, Inc.

Forward Citations = 1,509

311 inventors:

Wei Xu (26 out of 81 patents)

John M Nuss (26 out of 54 patents)

Yong Wang (24 out of 36 patents)

4. Lynne Canne Bannen (20 out of 24 patents)

5. James William Leahy (20 out of 25 patents)

Please report any incorrect information to support@idiyas.com

Loading…